Inclusion Criteria:

          -  Measurable stage IVA, stage IVB (with or without measurable disease) or recurrent
             (with or without measurable disease) endometrial carcinoma

               -  NOTE: histologic confirmation of the original primary tumor is required; patients
                  with the following histologic epithelial cell types are eligible: Endometrioid
                  adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell
                  adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not
                  otherwise specified (NOS)

               -  NOTE: measurable disease is defined by Response Evaluation Criteria in Solid
                  Tumors (RECIST) (version 1.1)

          -  Group A only: Largest tumor diameter =< 5 cm

               -  NOTE: Group B patients have no maximum tumor size

          -  Absolute neutrophil count (ANC) >= 1500/uL (obtained =< 14 days prior to registration)

          -  Platelet count (PLT) >= 100,000/uL (obtained =< 14 days prior to registration)

          -  Hemoglobin >= 10 g/dL (obtained =< 14 days prior to registration)

          -  Creatinine =< 2.0 mg/dL (obtained =< 14 days prior to registration)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit
             of normal (ULN) (obtained =< 14 days prior to registration)

               -  NOTE: if baseline liver disease, Child Pugh score not exceeding class A

          -  Total bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)

          -  International normalized ratio (INR)/prothrombin time (PT), activated partial
             thromboplastin time (aPTT) =< 1.4 x ULN (obtained =< 14 days prior to registration)
             unless on therapeutic warfarin then INR/PT =< 3.5

          -  Ability to provide written informed consent

          -  Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up

          -  Life expectancy >= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Willingness to provide mandatory biological specimens for research purposes

          -  Prior therapy:

               -  Any number of prior chemotherapy regimens and/or targeted therapies and/or prior
                  external beam radiation therapy and/or prior hormonal therapy for endometrial
                  cancer are allowed provided the last treatment was > 4 weeks prior to
                  registration

               -  Vaginal brachytherapy may have been administered at any time prior to
                  registration

        Exclusion Criteria:

          -  Availability of and patient acceptance of curative therapy

          -  Active infection, including any active viral infection, =< 5 days prior to
             registration

          -  Active or latent tuberculosis or hepatitis

          -  Known untreated or symptomatic brain metastases

          -  Any of the following prior therapies:

               -  Chemotherapy < 4 weeks prior to registration

               -  Targeted biologic therapy < 4 weeks prior to registration

               -  Immunotherapy < 4 weeks prior to registration

               -  Any viral or gene therapy prior to registration

               -  External beam radiotherapy < 4 weeks prior to registration

                    -  NOTE: Vaginal brachytherapy may be performed at any time prior to
                       registration

          -  New York Heart Association classification III or IV, known symptomatic coronary artery
             disease, or symptoms of coronary artery disease on systems review, or uncontrolled
             current cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia
             [SVT])

          -  Active central nervous system (CNS) disorder or seizure disorder or known CNS disease
             or neurologic symptomatology

          -  Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or
             immunosuppression

          -  History of hepatitis B or C or chronic hepatitis

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational (used for a non-Food and Drug Administration [FDA] approved
             indication and in the context of a research investigation)

          -  Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled
             steroids

          -  Exposure to household contacts =< 15 months old or household contact with known
             immunodeficiency

          -  Any of the following because this study involves an investigational agent whose
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are
             unknown:

               -  Pregnant persons or persons of reproductive ability who are unwilling to use
                  effective contraception

               -  Nursing persons

          -  Any other pathology or condition that the principal investigator deems to negatively
             impact treatment safety

          -  Any immunotherapy-related adverse events Common Terminology Criteria for Adverse
             Events (CTCAE) > grade 1 at the time of registration

          -  Receipt of a live virus vaccine =< 2 months prior to registration